$NTLA
Intellia Therapeutics, Inc
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
$12.14
▼-0.98%-$0.120
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateIntellia Therapeutics, Inc
XNAS•Health Care•In Vitro & in Vivo Diagnostic Substances
Why is NTLA down today? It is at $12.14 (-0.98%), and our scanner flagged it 186 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment NTLA spikes, and full due diligence on NTLA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $NTLA 186 times in the last 30 days. Create a free account to track $NTLA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on NTLA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for NTLA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Latest filing8-KRegulation FD Disclosure, Other Material EventSep 8, 2026 · 11 days ago| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Leonard John M Officer | Sold (automatic/other) | -3K | sold 0.2% | 1.15M | $36K at $13.00 | Aug 21, 26 |
Leonard John M Officer | Sold (automatic/other) | -20K 0.01% of company | sold 1.7% | 1.15M | $251K at $12.60 | Aug 20, 26 |
Dulac Edward J Iii Officer | Sold (automatic/other) | -8K | sold 5.2% | 148K | $91K at $11.25 | Jul 22, 26 |
Dulac Edward J Iii Officer | Sold (automatic/other) | -5K | sold 2.9% | 156K | $84K at $18.00 | Jul 2, 26 |
Dube Michael P Officer | Sold (automatic/other) | -3K | sold 3.8% | 67K | $44K at $16.78 | Jul 1, 26 |
Bhanji Muna Director | Acquired (grant/award) | +9K | added 34% | 36K | n/a | Jun 9, 26 |
Chase William J Director | Acquired (grant/award) | +9K | added 6.8% | 144K | n/a | Jun 9, 26 |
Cohen Fred E Director | Acquired (grant/award) | +9K | added 4.4% | 217K | n/a | Jun 9, 26 |
Goff Brian Director | Acquired (grant/award) | +9K | added 39% | 33K | n/a | Jun 9, 26 |
Goodman Jesse Director | Acquired (grant/award) | +9K | added 38% | 34K | n/a | Jun 9, 26 |
Keresty Georgia Director | Acquired (grant/award) | +9K | added 29% | 41K | n/a | Jun 9, 26 |
Verwiel Frank Director | Acquired (grant/award) | +9K | added 35% | 35K | n/a | Jun 9, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in in vitro & in vivo diagnostic substances, closest in size first.
Here is the latest on NTLA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for NTLA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
NTLA last traded at $12.14, down 0.98% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Intellia Therapeutics, Inc (NTLA) is next expected to report earnings on Thursday, November 5, 2026, about 46 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The NTLA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged NTLA 186 times in the last 30 days.
NTLA (Intellia Therapeutics, Inc) trades on XNAS, with a market cap of about $1.70B in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge NTLA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$NTLA discussion
Sign in to ask a question or join the discussion.